Clinical Trial

Safety Follow-up Study of Participants Dosed With INV-347 in Study INV-CL-108

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The study looks at the safety and blood levels of the study drug INV-347 in participants who were previously dosed with INV-347 in study INV-CL-108. Participants will not get any study drug in this study as it looks into the safety of a drug previously dosed. The study will last until visit 21.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-25.
Trial Details
NCT Number NCT07153172
Lead Sponsor Novo Nordisk A/S
Conditions Obesity
Enrollment 91 participants
Start Date 2025-08-06
Primary Completion 2027-09-15 (estimated)
Study Completion 2027-09-15 (estimated)
Updated on ClinicalTrials.gov 2026-03-06